SCHEMBL79543

SCHEMBL79543

CC(C)c1ccoc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827019 0.87 ALOX5 (0.40)
SCHEMBL14008529 0.79 ALOX5 (0.44)
SCHEMBL19852428 0.79
SCHEMBL142208 0.79
SCHEMBL11803243 0.79 ALOX5 (0.44)
SCHEMBL2008983 0.79
SCHEMBL3949654 0.79
SCHEMBL25007029 0.75 ALOX5 (0.42)
SCHEMBL8053657 0.75
SCHEMBL13406866 0.75 ALOX5 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3972596-A1 COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES Pfizer Inc. (US) 2022-03-30 EP claimed
CN-118388412-A Method for preparing 6- (4-amino-2, 6-dichlorophenoxy) -4-isopropyl pyridazin-3 (2H) -ketone 四川伊诺达博医药科技有限公司 2024-07-26 CN disclosed
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2024-06-27 US disclosed
EP-4359382-A1 TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS Chevron Phillips Chemical Company LP (US) 2024-05-01 EP disclosed
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2005068460-A1 ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2005-07-28 WO disclosed
WO-2005066147-A1 THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2005-07-21 WO disclosed
EP-1551818-A1 THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS Pharmacopeia Drug Discovery, Inc. (US) 2005-07-13 EP disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed
US-20040186142-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands SCHERING CORPORATION PHARMACOPEIA, INC. 2004-09-23 US disclosed
WO-2004033440-A1 THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2004-04-22 WO disclosed
EP-0390878-A1 OPTICALLY ANISOTROPIC PHOTOCHROMIC MATERIALS AND APPLICATIONS PLESSEY OVERSEAS LIMITED (GB) 1990-10-10 EP disclosed
WO-1989011674-A1 OPTICALLY ANISOTROPIC PHOTOCHROMIC MATERIALS AND APPLICATIONS PLESSEY OVERSEAS LIMITED (GB) 1989-11-30 WO disclosed
US-4017461-A Method for manufacturing liquid resinous furan-formaldehyde condensation products THE QUAKER OATS COMPANY (US) 1977-04-12 US disclosed